Coya Therapeutics Inc
NASDAQ:COYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Coya Therapeutics Inc
NASDAQ:COYA
|
US |
Coya Therapeutics Inc
Coya Therapeutics is a biotechnology company that develops treatments based on regulatory T cells, a type of immune cell that helps calm harmful inflammation. Its main work is to turn this science into therapies for diseases where the immune system and inflammation damage tissues, especially in neurodegenerative and autoimmune conditions. The company is still focused on research and clinical development rather than selling approved medicines. Coya’s lead programs are drug candidates and cell-based approaches aimed at slowing or changing the course of diseases rather than only treating symptoms. It works with hospitals, research partners, and clinical sites to test these therapies in patients. The company is trying to build a platform around immune regulation, which gives it more than one possible drug program from the same underlying science. Coya makes money the way most early-stage biotech companies do: through financing from investors, and potentially through future partnerships or licensing deals if its programs advance. Its business model is different from a traditional drug maker because it does not yet earn money from approved products; instead, it is trying to create value by developing a new class of immune-based therapies that could be used in hard-to-treat diseases.
Coya Therapeutics is a biotechnology company that develops treatments based on regulatory T cells, a type of immune cell that helps calm harmful inflammation. Its main work is to turn this science into therapies for diseases where the immune system and inflammation damage tissues, especially in neurodegenerative and autoimmune conditions. The company is still focused on research and clinical development rather than selling approved medicines.
Coya’s lead programs are drug candidates and cell-based approaches aimed at slowing or changing the course of diseases rather than only treating symptoms. It works with hospitals, research partners, and clinical sites to test these therapies in patients. The company is trying to build a platform around immune regulation, which gives it more than one possible drug program from the same underlying science.
Coya makes money the way most early-stage biotech companies do: through financing from investors, and potentially through future partnerships or licensing deals if its programs advance. Its business model is different from a traditional drug maker because it does not yet earn money from approved products; instead, it is trying to create value by developing a new class of immune-based therapies that could be used in hard-to-treat diseases.
